110 patents
Utility
Hetero-halo inhibitors of histone deacetylase
2 Jan 24
This invention provides compounds that are inhibitors of HDAC2.
Martin R. Jefson, John A. Lowe, III, Fabian Dey, Andreas Bergmann, Andreas Schoop, Nathan Oliver Fuller
Filed: 28 Dec 20
Utility
Immunostimulatory agents in combination with angiogenesis inhibitors
5 Dec 23
The invention provides compositions and methods of treating cancer in a patient with a combination therapy comprising administering to the patient a fusion protein of SEQ ID NO: 1, in combination with an angiogenesis inhibitor (e.g., an anti-VEGF antibody or lenvatinib).
Jared Lopes, Heather C. Losey, Raymond J. Winquist
Filed: 15 Apr 21
Utility
Substituted Macrocyclic Compounds and Related Methods of Treatment
26 Oct 23
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof.
Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
Filed: 22 Nov 22
Utility
Methods for treating antipsychotic-induced weight gain
24 Oct 23
The present invention relates to the discovery of a novel opioid modulator effective in reducing pharmacologically induced weight gain associated with atypical antipsychotic use.
Daniel R. Deaver, Mark Todtenkopf
Filed: 20 Oct 21
Utility
Sustained release aminopyridine composition
17 Oct 23
A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.
Sean Cunningham, Seamus Mulligan, Michael Myers
Filed: 22 Jun 22
Utility
Immediate Release Multilayer Tablet
5 Oct 23
Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Filed: 1 Jun 23
Utility
Methods of Administering Intravenous Meloxicam In a Bolus Dose
28 Sep 23
The present disclosure relates to meloxicam bolus formulations and methods of administering the same intravenously, for treatment of pain, which can provide fast onset of pain relief suitable for management of acute moderate to severe pain.
Randall J. MACK, Alex FREYER
Filed: 18 Aug 22
Utility
Sustained Release Aminopyridine Composition
21 Sep 23
A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hours or more and the use of the composition to treat various neurological diseases.
Sean Cunningham, Seamus Mulligan, Michael Myers
Filed: 18 Apr 23
Utility
Substituted piperidino compounds and related methods of treatment
19 Sep 23
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof.
Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Brian Kenneth Raymer, Jörg Martin Bentzien, Jonathan Ward Lehmann, Srinivasa Karra, Roman A. Valiulin, Daljit Matharu
Filed: 20 Dec 21
Utility
Reduction of flake-like aggregation in nanoparticulate active agent compositions
8 Aug 23
This invention is directed to reduction of flake-like aggregation in nanoparticulate compositions.
Niels P. Ryde, Peter Snyder, Wei Liu, David M. Slifer
Filed: 3 Dec 21
Utility
Immediate release multilayer tablet
25 Jul 23
Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Filed: 30 Jun 22
Utility
Methods for Treating Depressive Symptoms
25 May 23
The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Filed: 18 Nov 22
Utility
Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders
18 May 23
Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
Filed: 31 Oct 22
Utility
Aripiprazole Formulations Having Increased Injection Speeds
26 Jan 23
The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.
Magali B. Hickey, Jennifer Vandiver
Filed: 29 Jun 22
Utility
Substituted macrocyclic compounds and related methods of treatment
3 Jan 23
The present invention provides compounds useful for the treatment of narcolepsy or cataplexy in a subject in need thereof.
Lewis D. Pennington, Younggi Choi, Hoan Huynh, Brian M. Aquila, Ingo Andreas Mugge, Yuan Hu, James R. Woods, Roman A. Valiulin, Brian Kenneth Raymer, Jörg Martin Bentzien, Michael R. Hale, Jonathan Ward Lehmann, Daljit Matharu, Srinivasa Karra
Filed: 25 Nov 20
Utility
Methods for treating depressive symptoms
27 Dec 22
The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof.
Laura Cook Blumberg, Daniel R. Deaver, David J. Eyerman, Thomas Andrew Wynn
Filed: 26 Jun 20
Utility
Compositions and methods for modulating IL-10 immunostimulatory and anti-inflammatory properties
27 Dec 22
Demetri T. Moustakas, Mark N. Namchuk, Heather C. Losey, Juan C. Alvarez
Filed: 16 May 19
Utility
Sustained Release Aminopyridine Composition
22 Dec 22
A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.
Sean Cunningham, Seamus Mulligan, Michael Myers
Filed: 22 Jun 22
Utility
Heterocyclic compounds for the treatment of neurological and psychological disorders
6 Dec 22
Julius F. Remenar, Laura Cook Blumberg, Tarek A. Zeidan
Filed: 14 Sep 20
Utility
Immediate Release Multilayer Tablet
10 Nov 22
Described herein, in part, are tablets, such as immediate release multi-layer or bilayer tablets for orally delivering olanzapine and samidorphan, methods of using said tablets in the treatment of disorders described herein, and kits comprising said tablets.
Renato A. Chiarella, Hector Guzman, Paul Hurley, David Manser, Kristopher Perkin
Filed: 30 Jun 22